[25] Y Kai, et al. (2026). DISSECTING THE MOLECULAR BASIS OF POTENT HBF INDUCTION BY BMS-986470: A MECHANISTIC STUDY OF ZBTB7A/WIZ DUAL DEGRADATION. EHA Library. European Hematology Association Annual Congress 2026; Stockholm, Sweden.

[24] S Tamim, N Stong, Y Kai, D Jankeel, B Gaffney, A Kurtova, AR Perez, C Fontanillo, TT Chow, PR Hagner, D Jeyaraju, CC Bjorklund, M Amatangelo, K Wang, A Gandhi, M Ortiz-Estevez (2026). Development of a novel Ikaros/Aiolos transcriptional signature and correlation with patient response in multiple myeloma patients treated with CELMoDs. Cancer Research 86 (7 Suppl), Abstract nr 2714. AACR Annual Meeting 2026; San Diego, CA.

[23] Z Mo, L Groocock, S Wood, D Jankeel, D Mendy, ER Watson, Y Kai, et al. (2025). Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 For Diffuse Large B-Cell Lymphoma. Blood Cancer Discovery.

[22] Y Zhang*, S Zhou*, Yan Kai*, Y Zhang, C Peng, Z Li, MJ Mughal, B Julie, et al. (2024). O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer. Nature Communications 15 (1), 5597.

[21] T Liu, Q Zhu, Y Kai, T Bingham, S Wang, HJ Cha, S Mehta, TM Schlaeger, et al. (2024). Matrin3 mediates differentiation through stabilizing chromatin loop-domain interactions and YY1 mediated enhancer-promoter interactions. Nature Communications 15 (1), 1274.

[20] S Mehta, A Buyanbat, Y Kai, SH Orkin (2024). Mechanistic and kinetic insights into Transcription factor biology via acute protein depletion. Experimental Hematology, 104250.

[19] Yan Kai, N Liu, SH Orkin, GC Yuan (2023). Identifying Quantitatively Differential Chromosomal Compartmentalization Changes and Their Biological Significance from Hi-C data using DARIC. BMC Genomics.

[18] SN Olsen, L Godfrey, JP Healy, YA Choi, Y Kai, C Hatton, F Perner, et al. (2022). MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape. Molecular Cell 82 (6), 1140-1155.e11.

[17] N Weng, J Kim, T Nguyen, J Cifello, R Ahmad, Y Zhang, Q Yang, JE Lee, et al. (2022). Lysine methyltransferase Kmt2d regulates naive CD8+ T cell activation-induced survival. Frontiers in Immunology 13, 8240.

[16] T Harada, Y Heshmati, J Kalfon, MW Perez, JX Ferrucio, J Ewers, et al. (2022). A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia. Genes & Development 36 (5-6), 368-389.

[15] S Mehta*, A Buyanbat*, Yan Kai*, O Karayel, SR Goldman, D Seruggia, et al. (2022). Temporal resolution of gene derepression and proteome changes upon PROTAC-mediated degradation of BCL11A protein in erythroid cells. Cell Chemical Biology.

[14] N Liu, S Xu, Q Yao, Q Zhu, Yan Kai, JY Hsu, P Sakon, L Pinello, GC Yuan, et al. (2021). Transcription factor competition at the γ-globin promoters controls hemoglobin switching. Nature Genetics 53 (4), 511-520.

[13] Yan Kai, BE Li, M Zhu, GY Li, F Chen, Y Han, HJ Cha, SH Orkin, W Cai, et al. (2021). Mapping the evolving landscape of super-enhancers during cell differentiation. Genome Biology 22, 1-21.

[12] HJ Cha, Ö Uyan*, Y Kai*, T Liu, Q Zhu, Z Tothova, GA Botten, J Xu, et al. (2021). Inner nuclear protein Matrin-3 coordinates cell differentiation by stabilizing chromatin architecture. Nature Communications 12 (1), 1-19.

[11] S Perkail, J Andricovich, Y Kai, A Tzatsos (2020). BAP1 is a haploinsufficient tumor suppressor linking chronic pancreatitis to pancreatic cancer in mice. Nature Communications 11 (1), 3018.

[10] Y Zhang*, X Wu*, Y Kai*, CH Lee, F Cheng, Y Li, Y Zhuang, et al. (2019). Secretome profiling identifies neuron-derived neurotrophic factor as a tumor-suppressive factor in lung cancer. JCI Insight 4 (24).

[9] J Sun, X Cai, MMH Yung, W Zhou, J Li, Y Zhang, Z Li, SS Liu, et al. (2019). miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer. Oncogene 38 (4), 564.

[8] J Andricovich, S Perkail, Yan Kai, N Casasanta, W Peng, A Tzatsos (2018). Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors. Cancer Cell 33 (3), 512-526.e8.

[7] W Zhou, W Sun, MMH Yung, S Dai, Y Cai, CW Chen, Y Meng, JB Lee, et al. (2018). Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance. Oncogene, 1.

[6] Y Meng, CW Chen, MMH Yung, W Sun, J Sun, Z Li, J Li, Z Li, W Zhou, et al. (2018). DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer. Cancer Letters.

[5] Yan Kai, J Andricovich, Z Zeng, J Zhu, A Tzatsos, W Peng (2018). Predicting CTCF-mediated chromatin interactions by integrating genomic and epigenomic features. Nature Communications 9 (1), 4221.

[4] L Phan, J Hsu, M Willi, T Mansour, Y Kai, J Garner, J Lopez, B Busby (2017). dbVar structural variant cluster set for data analysis and variant comparison. F1000Research 5.

[3] J Andricovich, Y Kai, A Tzatsos (2016). Lysine-specific histone demethylases in normal and malignant hematopoiesis. Experimental Hematology 44 (9), 778-782.

[2] J Andricovich, Y Kai, W Peng, A Foudi, A Tzatsos (2016). Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis. Journal of Clinical Investigation.

[1] J Yin, R Chang, Y Kai, X Zhao (2013). Highly stable and AC electric field-activated electrorheological fluid based on mesoporous silica-coated graphene nanosheets. Soft Matter 9 (15), 3910-3914.